Diese Veranstaltung hat bereits stattgefunden

Web-Seminar

So12 Molecular Therapies - Neuroprotection

Symposiumof the section DOG-genetics, DOG 2020 Online
online, Deutschland
Veranstaltungsnummer: 34022
Zertifizierung: beantragt
Gebühren ab: 0,00 €
verfügbare Plätze: unbegrenzt
Sprache: Deutsch

 Zum Kalender hinzufügen
  • Datum
    11.10.2020, 13:30 - 14:15
    Veranstalter
    DOG - Deutsche Ophthalmologische Gesellschaft e.V.
    Kurzbeschreibung
    Recent advances in the understanding of the pathogenesis of retinal diseases have paved the way for the development of new therapeutic approaches. Protein homeostasis has been shown to be important in keeping cellular mechanisms functioning, and once this homeostasis is severely affected, survival of the cells is no longer granted, independent of the underlying pathology.
    Gebühren

    Fachärzte

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    120,00 €
    Hinweis
    This symposium is part of the DOG congress 2020 (9.-11.2020). The attandance for the total congress costs 250€ for members and 120€ for non-members.

    Ärzte/-innen in Weiterbildung

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    120,00 €
    Hinweis
    This symposium is part of the DOG congress 2020 (9.-11.2020). The attandance for the total congress costs 250€ for members and 120€ for non-members.

    Studenten/-innen

    Teilnehmer max.
    unbegrenzt

    Gebühren ab
    kostenlos
    Hinweis
    The full congress is free for students and PhD students.
  • Organisator/Vorsitzender: Knut Stieger | Gießen
    Vorsitzender: Marius Adler | Dresden

    One important pathway that has re-entered center stage is therefore neuroprotection for which several newly identified regulators of cell survival and viability have been identified. Preclinical studies are promising and the start of first in-human trials are likely to follow soon. The approval of Luxturna gene therapy in Europe in November 2018 has resulted in the treatment of a number of patients all over Europe, but has also shown that legislation and institutional support for this new class of medication can be important hurdles.

     

    So12-01
    13:30
    13:45

    Proteome centric target discovery for photoreceptor protection: the p97/VCP story

    Due to high production rates in visual pigment and high metabolic activity photoreceptor cells are especially vulnerable to defects in protein homeostasis. The ATPase Valosine Containing Protein (p97/VCP) acts as a protein quality control checkpoint of membrane proteins and binds to rhodopsin before the protein is released from the ER towards plasma membrane localization. Inhibiting VCP ATPase activity pharmacologically, we have generated evidence for a strong and long-lasting rescue of degenerating rod photoreceptors in the RhoP23H transgenic rat suggesting VCP as a target to treat autosomal dominant RP. Protection correlates with restoration of physiological rhodopsin trafficking to rod outer segments, improved rod OS ultrastructure and an improved ERG after intravitreal injection of the inhibitors.

    Marius Ueffing | Tübingen

    So12-02
    13:45
    14:00

    Retinoic acid receptor inhibitors in retinal diseases

    Richard Kramer | Berkeley/USA

    So12-03
    14:00
    14:15

    Proteostasis in retinal disease

    Ronald Roepman | Nijmegen/NL
  • This symposium is virtual. Saal von Graefe

    INTERPLAN AG
    Congress, Meeting & Event Management AG
    Landsberger Straße 155
    DE - 80687 München
    Tel.: +49 (0)89 548 234 35
    Tel.: +49 (0)89 548 234 0
    Fax: +49 (0)89 548 234 43
    Fax: +49 (0)89 548 234 44

  • Registration required. Please contact the organizer for further information.